All of the statements are true about Brugada syndrome, EXCEPT:
Transient ST segment elevation in lead V1-V3 is seen
Responsible for the sudden and unexpected nocturnal death syndrome
Risk of fatal ventricular arrhythmia is more
Flecainide can be used to treat
The major clinical features of Brugada syndrome include, transient, or concealed ST segment elevation in V1 to V3 that typically can be provoked with the sodium channel-blocking drugs flecainide, and procainamide and a risk of polymorphic ventricular arrhythmias. Ref: Harrisons Principles of Internal Medicine, 18th Edition, Page 1898.